Subcutaneous administration of botulinum toxin A reduces formalin-induced pain
Top Cited Papers
- 1 January 2004
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Pain
- Vol. 107 (1), 125-133
- https://doi.org/10.1016/j.pain.2003.10.008
Abstract
Botulinum toxin type A (BoNT-A) produced by the bacterium Clostridium botulinum is a potent inhibitor of acetylcholine release in the neuromuscular junction and has been used to treat many disorders related to excessive muscle contraction. However, BoNT-A has recently been used in pain theraKeywords
This publication has 54 references indexed in Scilit:
- Botulinum toxin type A (BOTOX) for treatment of migraine headaches: An open-label studyOtolaryngology -- Head and Neck Surgery, 2000
- Inflammation-induced changes in peripheral glutamate receptor populationsBrain Research, 1999
- Primary afferent tachykinins are required to experience moderate to intense painNature, 1998
- Calcitonin gene-related peptide: Vasoactive effects and potential therapeutic roleGeneral Pharmacology: The Vascular System, 1996
- Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasmMovement Disorders, 1987
- The primary afferent depolarizing action of kainate in the ratBritish Journal of Pharmacology, 1986
- Calcitonin gene-related peptide is a potent vasodilatorNature, 1985
- Tissue concentration and release of substance P-like immunoreactivity in the dental pulpActa Physiologica Scandinavica, 1981
- Axonal transport of substance P in the vagus and sciatic nerves of the guinea pigBrain Research, 1980
- Substance P: Release on trigeminal nerve stimulation, effects in the eyeActa Physiologica Scandinavica, 1979